{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:03:10Z","timestamp":1792533790608,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03597-3","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:56:45Z","timestamp":1772193405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multidomain clinical and biological remission with tezepelumab in severe asthma: a 12-month multicentre real-world study"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6407-5832","authenticated-orcid":false,"given":"Juan Luis","family":"Garc\u00eda-Rivero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Hannaoui Anaaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Pallar\u00e9s-Sanmart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Blanco-Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Garc\u00eda-Hern\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Garc\u00eda-Gallardo Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ux\u00edo","family":"Calvo-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Carazo-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Hermida-Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Dorronsoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Carrascosa-Anguiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Lobato Asti\u00e1rraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idania","family":"de los Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"Enr\u00edquez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Perez de Llano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"\u00c1lvarez Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Abascal-Bolado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Santiba\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"2","key":"3597_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343\u201373.","journal-title":"Eur Respir J"},{"key":"3597_CR2","unstructured":"Global Strategy for Asthma Management and Prevention. Available at https:\/\/ginasthma.org\/reports\/. Accessed February 4, 2024 2023."},{"issue":"1","key":"3597_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jaip.2022.10.015","volume":"11","author":"WW Busse","year":"2023","unstructured":"Busse WW, Castro M, Casale TB. Asthma Management in Adults. J allergy Clin Immunol Pract. 2023;11(1):21\u201333.","journal-title":"J allergy Clin Immunol Pract"},{"issue":"2","key":"3597_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","volume":"386","author":"GG Brusselle","year":"2022","unstructured":"Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med. 2022;386(2):157\u201371.","journal-title":"N Engl J Med"},{"key":"3597_CR5","doi-asserted-by":"publisher","unstructured":"Pelaia C, Pelaia G, Crimi C, Maglio A, Stanziola AA, Calabrese C, et al. Novel biological therapies for severe asthma endotypes. Biomedicines. 2022;10(5):1064. https:\/\/doi.org\/10.3390\/biomedicines10051064.","DOI":"10.3390\/biomedicines10051064"},{"issue":"1","key":"3597_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","volume":"15","author":"JV Fahy","year":"2015","unstructured":"Fahy JV. Type 2 inflammation in asthma\u2013present in most, absent in many. Nat Rev Immunol. 2015;15(1):57\u201365.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"3597_CR7","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.jaip.2022.01.040","volume":"10","author":"R Chan","year":"2022","unstructured":"Chan R, Stewart K, Misirovs R, Lipworth BJ. Targeting downstream Type 2 cytokines or upstream epithelial alarmins for severe asthma. J allergy Clin Immunol Pract. 2022;10(6):1497\u2013505.","journal-title":"J allergy Clin Immunol Pract"},{"key":"3597_CR8","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2147\/JAA.S275039","volume":"15","author":"JR Parnes","year":"2022","unstructured":"Parnes JR, Molfino NA, Colice G, Martin U, Corren J, Menzies-Gow A. Targeting TSLP in Asthma. J asthma allergy. 2022;15:749\u201365.","journal-title":"J asthma allergy"},{"key":"3597_CR9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren J, Garcia Gil E, Griffiths JM, Parnes JR, van der Merwe R, Sa\u0142apa K, et al. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. N Engl J Med. 2017;377:936\u201346.","journal-title":"N Engl J Med"},{"key":"3597_CR10","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Colice G, Griffiths JM, Almqvist G, Ponnarambil S, Kaur P, et al. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384:1800\u20139.","journal-title":"N Engl J Med"},{"key":"3597_CR11","doi-asserted-by":"publisher","unstructured":"Lugogo NL, Akuthota P, Sumino K, Mathur SK, Burnette AF, Lindsley AW, et al. Effectiveness and safety of tezepelumab in a diverse population of US patients with severe asthma: initial results of the PASSAGE Study. Adv Ther. 2025;42(7):3334\u201353. https:\/\/doi.org\/10.1007\/s12325-025-03231-6.","DOI":"10.1007\/s12325-025-03231-6"},{"key":"3597_CR12","doi-asserted-by":"publisher","unstructured":"Khateeb J, Kramer MR, Freund O, Mhameed R, Naamany E, Kupershmidt A, et al. Real-world evidence of tezepelumab for severe asthma: a retrospective multicentre cohort. ERJ Open Res. 2025;11(5):00314\u20132025. https:\/\/doi.org\/10.1183\/23120541.00314-2025.","DOI":"10.1183\/23120541.00314-2025"},{"key":"3597_CR13","doi-asserted-by":"publisher","unstructured":"Gates J, Haris F, Cefaloni F, Khooshemehri P, Green L, Fernandes M, et al. Clinical and biological remission with tezepelumab: the real-world response in severe uncontrolled asthma. Allergy. 2025;80(6):1669\u201376. https:\/\/doi.org\/10.1111\/all.16590.","DOI":"10.1111\/all.16590"},{"key":"3597_CR14","doi-asserted-by":"publisher","unstructured":"Soendergaard MB, Haakansson KEJ, Hansen S, Bjerrum AS, Schmid JM, Johansson SL, et al. Tezepelumab in real-life practice: characteristics of patients commenced and efficacy in a nationwide, Danish cohort of patients with severe asthma. J Allergy Clin Immunol Pract. 2026;14(2):418\u201326. https:\/\/doi.org\/10.1016\/j.jaip.2025.09.001.","DOI":"10.1016\/j.jaip.2025.09.001"},{"key":"3597_CR15","doi-asserted-by":"publisher","unstructured":"Miralles-L\u00f3pez JC, And\u00fajar-Espinosa R, Bravo-Gutierrez FJ, Cabrejos-Perotti S, Ram\u00edrez-Hern\u00e1ndez M, D\u00edaz-Chantar C, et al; RE-ASGRAMUR GROUP. Tezepelumab in patients with severe asthma: response at 3 months. J Investig Allergol Clin Immunol. 2025;35(2):132\u20134. https:\/\/doi.org\/10.18176\/jiaci.1041.","DOI":"10.18176\/jiaci.1041"},{"issue":"5","key":"3597_CR16","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","volume":"39","author":"A Menzies-Gow","year":"2022","unstructured":"Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, et al. Clinical remission in severe asthma: a pooled Post Hoc Analysis of the patient journey with Benralizumab. Adv therapy. 2022;39(5):2065\u201384.","journal-title":"Adv therapy"},{"key":"3597_CR17","doi-asserted-by":"publisher","unstructured":"Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? Eur Respir J. 2022;60(5):2102583. https:\/\/doi.org\/10.1183\/13993003.02583-2021.","DOI":"10.1183\/13993003.02583-2021"},{"issue":"8","key":"3597_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.arbres.2024.04.002","volume":"60","author":"FJ \u00c1lvarez-Guti\u00e9rrez","year":"2024","unstructured":"\u00c1lvarez-Guti\u00e9rrez FJ, Casas-Maldonado F, Soto-Campos G, Blanco-Aparicio M, Delgado J, Galo AP, et al. Spanish Consensus on Remission in Asthma (REMAS). Arch Bronconeumol. 2024;60(8):503\u20139.","journal-title":"Arch Bronconeumol"},{"issue":"2","key":"3597_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pccm.2025.05.001","volume":"3","author":"S Thawanaphong","year":"2025","unstructured":"Thawanaphong S, Nolasco S, Nair P. Achieving remission in severe asthma. Chin Med J Pulm Crit Care Med. 2025;3(2):77\u201387.","journal-title":"Chin Med J Pulm Crit Care Med"},{"issue":"1","key":"3597_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","volume":"13","author":"A Shackleford","year":"2025","unstructured":"Shackleford A, Heaney LG, Redmond C, McDowell PJ, Busby J. Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis. Lancet Respiratory Med. 2025;13(1):23\u201334.","journal-title":"Lancet Respiratory Med"},{"key":"3597_CR21","doi-asserted-by":"publisher","unstructured":"Jackson DJ, Pavord ID, Virchow JC, Parnes JR, Gamil A, Hunter G, et al. The proportion of patients achieving low biomarker levels with tezepelumab treatment in the phase 3 NAVIGATOR study. Eur Respir J. 2023;62(suppl 67):OA1418. https:\/\/doi.org\/10.1183\/13993003.congress-2023.OA1418.","DOI":"10.1183\/13993003.congress-2023.OA1418"},{"issue":"9","key":"3597_CR22","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/jcm8091375","volume":"8","author":"A Bakakos","year":"2019","unstructured":"Bakakos A, Loukides S, Bakakos P. Severe Eosinophilic Asthma. J Clin Med. 2019;8(9):1375.","journal-title":"J Clin Med"},{"issue":"19","key":"3597_CR23","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800\u20139.","journal-title":"N Engl J Med"},{"key":"3597_CR24","doi-asserted-by":"publisher","first-page":"106202","DOI":"10.1016\/j.rmed.2020.106202","volume":"175","author":"S Graff","year":"2020","unstructured":"Graff S, Bricmont N, Moermans C, Henket M, Paulus V, Guissard F, et al. Clinical and biological factors associated with irreversible airway obstruction in adult asthma. Respir Med. 2020;175:106202.","journal-title":"Respir Med"},{"issue":"5","key":"3597_CR25","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1164\/ajrccm.164.5.2011026","volume":"164","author":"A ten Brinke","year":"2001","unstructured":"ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001;164(5):744\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3597_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1183\/09031936.04.00077803","volume":"24","author":"D Bumbacea","year":"2004","unstructured":"Bumbacea D, Campbell D, Nguyen L, Carr D, Barnes PJ, Robinson D, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J. 2004;24(1):122.","journal-title":"Eur Respir J"},{"issue":"3","key":"3597_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.resinv.2025.01.003","volume":"63","author":"K Matsunaga","year":"2025","unstructured":"Matsunaga K, Koarai A, Koto H, Shirai T, Muraki M, Yamaguchi M, et al. Guidance for type 2 inflammatory biomarkers. Respiratory Invest. 2025;63(3):273\u201388.","journal-title":"Respiratory Invest"},{"issue":"6","key":"3597_CR28","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/all.15197","volume":"77","author":"J Corren","year":"2022","unstructured":"Corren J, Pham TH, Garcia Gil E, Sa\u0142apa K, Ren P, Parnes JR, et al. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy. 2022;77(6):1786\u201396.","journal-title":"Allergy"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03597-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03597-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03597-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T13:05:30Z","timestamp":1775221530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03597-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3597"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03597-3","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Clinical Research Ethics Committee of Cantabria (Spain) and was subsequently acknowledged by all participating centres. All patients provided written informed consent prior to inclusion, and the study was conducted in accordance with the Declaration of Helsinki and national regulations on observational research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript does not contain any individual person\u2019s data in any form (including individual images, videos or recordings).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}